APOLLO readout in Q4 2026 is the next major catalyst; monitor for enrollment updates or interim analysis. Positive data would likely drive significant upside; failure would be severely negative. Consider positioning ahead of APOLLO results.
IRON drugs
IRON drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 9 $68.34entry
- T+1 · 5mo ago −1.59%α −0.02% · $67.25
- T+5 · 5mo ago +2.56%α +0.15% · $70.09
- T+20 · 4mo ago +16.71%α +15.26% · $79.76
- T+60 · 3mo ago +17.13%α +13.32% · $80.05
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Disc Medicine announced alignment with the FDA that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for responding to the CRL for bitopertin in EPP and potentially support traditional approval. This provides a clearer path forward after the CRL, reducing regulatory uncertainty. APOLLO data is expected in Q4 2026, with an FDA decision by mid-2027.
Key Facts
- FDA aligned that successful Phase 3 APOLLO study can support CRL response and potentially traditional approval.
- APOLLO data expected in Q4 2026; CRL response submission by end of 2026.
- FDA decision on bitopertin expected by mid-2027.
- Bitopertin is a potential first disease-modifying therapy for EPP.
Financial Impact
Reduced regulatory risk; potential for approval by mid-2027 could unlock significant revenue for bitopertin in EPP.
Risk Factors
- APOLLO may fail to meet endpoints, leading to approval delay or denial.
- Competition from other EPP treatments or alternative therapies.
- Regulatory setbacks or additional CRL items
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308825 |
Track record
43 reports on IRON
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers